UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For themonth of September 2024
CommissionFile Number 001-15170
GSK plc
(Translationof registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Addressof principal executive office)
Indicateby check mark whether the registrant files or will file annualreports
under cover of Form 20-F or Form 40-F.
Form20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc
Total Voting Rights and Capital
Inconformity with the Financial Conduct Authority'sDisclosure Guidance and
Transparency Rule 5.6.1R, GSK plc (the'Company') hereby notifies the market of
thefollowing:
The Company's issued share capital as at 31 August 2024 consistedof4,314,232,277
shares of 31 pence each('Ordinary Shares'), of which169,171,155Ordinary
Shareswere held in Treasury.
Therefore, the total number of voting rights in the Companyis4,145,061,122.This
figure may be used by shareholdersas the denominator for the calculations by
which they willdetermine if they are required to notify their interest in, or
achange to their interest in, the Company under the FinancialConduct
Authority's Disclosure Guidance and TransparencyRules.
Notifications may be sent to
company.secretary@gsk.com
.
V A Whyte
Company Secretary
2 September 2024
SIGNATURES
Pursuantto the requirements of the Securities Exchange Act of 1934,
theregistrant has duly caused this report to be signed on its behalfby the
undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date:September02, 2024
By:/s/VICTORIAWHYTE
--------------------------
VictoriaWhyte
AuthorisedSignatory for and on
behalfof GSK plc